

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

DR. FALK PHARMA GMBH,
Petitioner

v.

ELLODI PHARMACEUTICALS, L.P.,
Patent Owner

Case No. PGR2025-00086
U.S. Patent No. 12,290,598 B2

PATENT OWNER'S UPDATED EXHIBIT LIST

TABLE OF EXHIBITS

Exhibit No.	Description of Document
2001	Request for Certificate of Correction for U.S. Patent No. 12,290,598
2002	Dellon, E.S. et al., Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial, Clinical Gastroenterology and Hepatology 20:2485–2494 (2022)
2003	Excerpt from the file history of U.S. Patent No. 10,632,069
2004	<i>Reserved</i>
2005	Iorgulescu, G., Saliva between normal and pathological. Important factors in determining systemic and oral health, Journal of Medicine and Life Vol. 2, No.3, July-September 2009, pp.303-307
2006	Miehkle, S. et al., A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis, Gut 0:1-10 (2015)
2007	Declaration of Martyn Christopher Davies in Support of Patent Owner's Preliminary Response
2008	<i>Curriculum Vitae</i> of Martyn Christopher Davies
2009	<i>Reserved</i>
2010	Clinical Trials Study, "Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)(FLUTE)," last updated Apr. 26, 2023, https://clinicaltrials.gov/study/NCT03191864?tab=results&a=11#outcome-measures
2011	Transcript of the April 9, 2025 Deposition of Alan F. Parr, Pharm.D., Ph.D. from No. IPR2024-01197

Patent Owner's Updated Exhibit List
PGR2025-00086
U.S. Patent No. 12,290,598 B2

Exhibit No.	Description of Document
2012	“Antrum” Definition, American Medical Dictionary: A Concise and Up-to-Date Guide to Medical Terms (1998)
2013	M.E. Aulton (Ed.), <i>Pharmaceutics: The Science of Dosage Form Design</i> (2d. 2002)
2014	“Lozenge” Definition, Dennis B. Worthen (ed.), <i>Dictionary of Pharmacy</i> (2004)
2015	Paul J. Sheskey et al., <i>Handbook of Pharmaceutical Excipients</i> (8d. 2017)
2016	Hahm, H.A., Augsburger, L.L., Ch. 9 Orally Disintegrating Tablets and Related Tablet Formulations
2017	Ghosh, T.K. et al, Drug Delivery to the Oral Cavity Molecules to Market, Ch. 14 Quick dissolving oral dosage forms: Scientific and regulatory considerations from a clinical pharmacology and Biopharmaceutics Perspective (2005)
2018	Transcript of the August 25, 2025 deposition of Alan Parr, Pharm.D. from No. IPR2024-01197
2019	<i>Reserved</i>
2020	Cordova-Fraga T, Sosa M, Wiechers C, et al., Effects of anatomical position on esophageal transit time: a biomagnetic diagnostic technique. <i>World J Gastroenterol</i> 14:5707–11 (2008)
2021	U.S. Patent No. 8,324,192
2022	Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, Patent and Exclusivity for: N213976, Product 001 Budesonide (Eohilia) Suspension 2mg/10ml, https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=213976&Appl_type=N

Patent Owner's Updated Exhibit List
PGR2025-00086
U.S. Patent No. 12,290,598 B2

Exhibit No.	Description of Document
2023	<i>Reserved</i>
2024	<i>Reserved</i>
2025	<i>Reserved</i>
2026	<i>Dr. Falk Pharma GMBH v. Ellodi Pharms., L.P.</i> , IPR2024-01197, EX1093 (P.T.A.B. July 10, 2024)
2027	<i>Reserved</i>
2028	<i>Reserved</i>
2029	<i>Reserved</i>
2030	<i>Reserved</i>
2031	Highlights of Prescribing Information for EOHILIA™
2032	Sonnegaard, J.M. et al., Comparative Investigations of Tablet Crushing Force Testers, Pharm. Ind. 67, Nr. 1, 109–115 (2005)
2033	Dr. Schleuniger® Pharmatron Tablet Hardness Measuring Technology, Key Factors Influencing measured tablet hardness (2011)
2034	USP <1151>, Pharmaceutical Dosage Forms, https://www.uspnf.com/sites/default/files/uspnf_pdf/EN/USPNF/pharmaceuticalDosageForms.pdf
2035	Declaration of Isha Agarwal

Patent Owner's Updated Exhibit List
PGR2025-00086
U.S. Patent No. 12,290,598 B2

Dated: January 7, 2026

Respectfully submitted,

COOLEY LLP
ATTN: Patent Group
1299 Pennsylvania Avenue NW
Suite 700
Washington, DC 20004
Tel: (202) 776-2982
Fax: (202) 842-7899

By: /Sanya Sukduang/
Sanya Sukduang
Reg. No. 46,390
Counsel for Patent Owner

Patent Owner's Updated Exhibit List
PGR2025-00086
U.S. Patent No. 12,290,598 B2

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. §§42.6(e)(4)(i) *et seq.*, a complete copy of the attached **PATENT OWNER'S UPDATED EXHIBIT LIST** is being served via electronic mail on the Petitioner by serving Petitioner's counsel of record as follows:

Nathanael Luman
Eric S. Furman
Philip J. Minnick
KNOBBE, MARTENS, OLSON, & BEAR, LLP
2nrl@knobbe.com
2esf@knobbe.com
2pjm@knobbe.com
BoxFalkPharma@knobbe.com

Dated: January 7, 2026

/Sanya Sukduang/
Sanya Sukduang
Reg. No. 46,390